[Vascular molecular markers for determination of disease free survival (DFS) of breast cancer].
The heterogeneity of the evolution of breast cancer complicates patient management. The use of vascular markers as prognostic factors is a new and promising tool in medical oncology. Research data of the current decade demonstrate that angiogenesis plays substantial role in growth and spread of malignant tumor. At present, immunohistochemical determination of intratumoral microvascular density represents one of the more promising new prognostic indicators in breast cancer that needs to be further investigated to identify and standardize the method of choice to be tested in prospective clinical studies. Consequently markers of angiogenic activity have receiving increasing attention. By analyzing the evolution of 209 cases of breast cancer enrolled in a prospective study reaching the 5th year of follow up, we provide herein data supporting that Factor VIII and CD34 could be reliable markers for prognosis of DFS. Tumors with lower expression of Factor VIII and CD34 have a better prognostic and lower potential metastatic. The Factor VIII comparative with CD34 represents a more faithful prognostic marker. Angiogenesis markers have also become a putative therapeutic target.
Hopulele
Dorina
D
Ambulatorul de Oncologie, Spitalul Clinic Universitar "Sf. Spiridon", Iaşi.
Zugun-Eloae
F
F
Cozma
Graziella Laurette
GL
Carasevici
E
E
D018952:Antigens, CD34 / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005169:Factor VIII / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000473:pathology*; D011379:Prognosis; D011446:Prospective Studies
D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D005169:Factor VIII